InhalerMRP Under Process
Official PMBI MRP is being updated for catalog code 2872.
Locate Jan Aushadhi KendraClinical Overview
Tiotropium Bromide (18mcg) and Formoterol Fumarate (12mcg, with or without Ciclesonide 400mcg / Inhaler / Rotacaps) is a dual/triple bronchodilator therapy for advanced COPD and severe refractory asthma. Tiotropium is a long-acting muscarinic antagonist (LAMA) with prolonged M3 receptor dissociation kinetics (>36 hours); formoterol is a fast-acting LABA; ciclesonide is an on-site activated corticosteroid prodrug. Indicated for maintenance treatment of severe COPD and persistent severe asthma with frequent exacerbations.
Active Pharmaceutical Ingredients
Verified Clinical References
Usage Guidelines
Inhale 1 rotacap or 1 to 2 puffs once or twice daily as directed using the inhalation device. Rinse mouth thoroughly with water and spit out if combination contains ciclesonide.
General Administration Advice: Adhere strictly to the prescribed dosage, frequency, and treatment course. For oral medications, swallow with sufficient water. Never stop antibiotics, psychiatric medications, or antihypertensives abruptly without clinical direction.
Possible Side Effects
Common: Dry mouth (common, resolves with continued use), pharyngitis, cough, headache, tremor, constipation. Rare/Severe: Paradoxical bronchospasm, acute urinary retention, and angle-closure glaucoma.
*Note: Individual physiological responses vary. While many patients experience few or no side effects, notify your treating physician if adverse reactions persist or if hypersensitivity (angioedema, skin rash, dyspnea) occurs.
Precautions & Warnings
Do not swallow capsules. Avoid spraying or inhaling powder near the eyes (can precipitate acute narrow-angle glaucoma). Caution in patients with bladder neck obstruction or prostatic hypertrophy.
Medical Disclaimer: Statutory Clinical Disclaimer: The information provided is for educational and price-transparency purposes only and does not constitute medical advice, pulmonological diagnosis, or respiratory management recommendations. Inhalation therapies and allergy medications should be used strictly under the guidance of a qualified pulmonologist or registered medical practitioner.
Formoterol 6mcg + Budesonide 200mcg Rotacaps
Formoterol Fumarate (6mcg/12mcg) and Budesonide (100mcg/200mcg/400mcg Inhaler, Rotacaps, Powder, or Nebuliser Suspension) is a gold-standard fixed-dose combination on the WHO Model List of Essential Medicines. Budesonide is a potent inhaled glucocorticoid that suppresses airway mucosal inflammation, reduces microvascular permeability, and decreases hyperresponsiveness. Formoterol is a rapid-onset, long-acting beta-2 adrenergic agonist (LABA) that stimulates adenylyl cyclase, relaxes bronchial smooth muscle within 1-3 minutes, and provides sustained bronchodilation for >12 hours. Recommended by GINA guidelines as preferred Maintenance and Reliever Therapy (SMART / MART). Indicated for maintenance and rescue relief of bronchial asthma and symptomatic maintenance of Chronic Obstructive Pulmonary Disease (COPD).
Tiotropium Bromide 18mcg + Formoterol Fumarate Dihydrate 12mcg Rotacaps
Tiotropium Bromide (18mcg) and Formoterol Fumarate (12mcg, with or without Ciclesonide 400mcg / Inhaler / Rotacaps) is a dual/triple bronchodilator therapy for advanced COPD and severe refractory asthma. Tiotropium is a long-acting muscarinic antagonist (LAMA) with prolonged M3 receptor dissociation kinetics (>36 hours); formoterol is a fast-acting LABA; ciclesonide is an on-site activated corticosteroid prodrug. Indicated for maintenance treatment of severe COPD and persistent severe asthma with frequent exacerbations.
Tiotropium Bromide 18mcg + Formoterol Fumarate Dihydrate 12mcg + Ciclesonide 400mcg Rotacaps
Tiotropium Bromide (18mcg) and Formoterol Fumarate (12mcg, with or without Ciclesonide 400mcg / Inhaler / Rotacaps) is a dual/triple bronchodilator therapy for advanced COPD and severe refractory asthma. Tiotropium is a long-acting muscarinic antagonist (LAMA) with prolonged M3 receptor dissociation kinetics (>36 hours); formoterol is a fast-acting LABA; ciclesonide is an on-site activated corticosteroid prodrug. Indicated for maintenance treatment of severe COPD and persistent severe asthma with frequent exacerbations.
Formoterol 6mcg + Fluticasone Propionate 250mcg Inhaler
Formoterol Fumarate (6mcg) and Fluticasone Propionate (250mcg Inhaler / Powder for Inhalation) combines a rapid-onset, long-acting beta-2 agonist with a high-affinity synthetic fluorinated corticosteroid. Delivers fast bronchodilation within minutes along with comprehensive mucosal anti-inflammatory suppression. Indicated for regular maintenance treatment of persistent asthma in patients not adequately controlled on inhaled corticosteroids alone.